Takeda Pharmaceutical Co (TSE:4502) Cyclically Adjusted Revenue per Share: 円2,624.65 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4502 Takeda Pharmaceutical Co Ltd TSE:4502
64 GF Score
Price 円5,505.00
GF Value 円4,543.41
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Takeda Pharmaceutical Co TSE:4502 -0.85% 64 Cyclically Adjusted Revenue per Share is 円2,624.65 as of Mar. 2026. GuruFocus rates TSE:4502 with a GF Score™ of 64/100 and a GF Value™ of 円4,543.41 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円693.052. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円2,624.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Takeda Pharmaceutical Co was 4.70% per year. The lowest was 1.10% per year. And the median was 2.50% per year.

As of today (2026-07-23), Takeda Pharmaceutical Co's current stock price is 円5505.00. Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円2,624.65. Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Takeda Pharmaceutical Co  (TSE:4502) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5505.00/2624.65
=2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takeda Pharmaceutical Co was 3.13. The lowest was 1.34. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,236.75 2,350.86 2,444.75 2,567.17 2,624.65

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,567.17 2,586.58 2,597.06 2,623.15 2,624.65

TSE:4502 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4502
64GF Score
Takeda Pharmaceutical Co Ltd TSE:4502
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=693.052/112.7000*112.7000
=693.052

Current CPI (Mar. 2026) = 112.7000.

Takeda Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 552.716 98.100 634.975
201609 531.824 98.000 611.598
201612 592.687 98.400 678.819
201703 528.106 98.100 606.703
201706 570.838 98.500 653.131
201709 551.286 98.800 628.845
201712 620.790 99.400 703.853
201803 508.234 99.200 577.399
201806 571.976 99.200 649.815
201809 546.891 99.900 616.963
201812 633.386 99.700 715.974
201903 461.294 99.700 521.443
201906 543.951 99.800 614.261
201909 519.185 100.100 584.537
201912 551.641 100.500 618.606
202003 490.555 100.300 551.202
202006 511.998 99.900 577.599
202009 501.530 99.900 565.790
202012 531.035 99.300 602.695
202103 489.225 99.900 551.908
202106 610.933 99.500 691.981
202109 534.553 100.100 601.839
202112 572.279 100.100 644.314
202203 554.178 101.100 617.763
202206 625.628 101.800 692.616
202209 640.971 103.100 700.654
202212 698.255 104.100 755.940
202303 603.672 104.400 651.665
202306 676.416 105.200 724.640
202309 666.385 106.200 707.171
202312 688.132 106.800 726.147
202403 662.862 107.200 696.871
202406 760.193 108.200 791.809
202409 730.669 108.900 756.165
202412 710.617 110.700 723.456
202503 653.207 111.100 662.614
202506 696.828 111.700 703.066
202509 693.898 112.000 698.235
202512 742.345 113.000 740.374
202603 693.052 112.700 693.052

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円2,624.65 mean?
Takeda Pharmaceutical Co (TSE:4502) has a Cyclically Adjusted Revenue per Share of 円2,624.65 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Takeda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,624.65. Overall, Takeda Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円2,624.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,624.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,543.41, compared to a current price of 円5,505.00 — trading 21.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円2,624.65. Takeda Pharmaceutical Co's overall GF Score™ is 64/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current Cyclically Adjusted Revenue per Share is 円2,624.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,505.00 is trading 21.2% above its estimated GF Value™ of 円4,543.41. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4502:

  • Cyclically Adjusted Revenue per Share: 円2,624.65
  • GF Value™: 円4,543.41 vs. price of 円5,505.00 (21.2% above fair value)
  • GF Score™: 64/100 with 10 warning signs

No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
64GF Score

Get the complete analysis for TSE:4502

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,505.00
Price
円4,543.41
GF Value